Celltrion (068270) Stock Outlook 2026: ZYMFENTRA's US Launch and Biosimilar Growth
Celltrion (068270) 2026 outlook for US investors: ZYMFENTRA subcutaneous infliximab US market penetration, PBM formulary dynamics, pipeline beyond the first wave, and how to access this Korean biosimilar leader through OTC markets or ETFs.